New treatment option for ovarian cancer: PARP inhibitors

por Meehan, Robert S., Chen, Alice P.
Publicado 2016

Evaluation of patient outcomes after operative treatment of intra-articular calcaneus fractures

por Steelman, Kevin, Bolz, Nicholas, Feria-Arias, Enrique, Meehan, Robert
Publicado 2021

PARP Inhibitors in Reproductive System Cancers: Current Use and Developments

por O’Sullivan Coyne, Geraldine, Chen, Alice P., Meehan, Robert, Doroshow, James H.
Publicado 2017

A Phase I Study of Ganetespib and Ziv‐Aflibercept in Patients with Advanced Carcinomas and Sarcomas

por Meehan, Robert, Kummar, Shivaani, Do, Khanh, O'Sullivan Coyne, Geraldine, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Doroshow, James H., Chen, Alice P.
Publicado 2018

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

por O'Sullivan Coyne, Geraldine, Kummar, Shivaani, Hu, James, Ganjoo, Kristen, Chow, Warren A., Do, Khanh T., Zlott, Jennifer, Bruns, Ashley, Rubinstein, Lawrence, Foster, Jared C., Juwara, Lamin, Meehan, Robert, Piekarz, Richard, Streicher, Howard, Sharon, Elad, Takebe, Naoko, Voth, Andrea Regier, Bottaro, Donald, Costello, Rene, Wright, John J., Doroshow, James H., Chen, Alice P.
Publicado 2022

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

por Coyne, Geraldine O'Sullivan, Kummar, Shivaani, Meehan, Robert S., Do, Khanh, Collins, Jerry M., Anderson, Larry, Ishii, Kazusa, Takebe, Naoko, Zlott, Jennifer, Juwara, Lamin, Piekarz, Richard, Streicher, Howard, Sharon, Elad, Rubinstein, Larry, Voth, Andrea Regier, Lozier, Jay, Dull, Angie B., Wilsker, Deborah, Hinoue, Toshinori, Laird, Peter W., Ferry-Galow, Katherine V., Kinders, Robert J., Parchment, Ralph E., Doroshow, James H., Chen, Alice P.
Publicado 2020